Risk factors for capillary C4d deposition in kidney allografts: Evaluation of a large study cohort

Transplantation

Volumn 78, Issue 3, 2004, Pages 447-452

  Lorenz, Matthias ^a   Regele, Heinz ^a   Schillinger, Martin ^a   Exner, Markus ^a   Rasoul Rockenschaub, Susanne ^a   Wahrmann, Markus ^a   Kletzmayr, Josef ^a   Silberhumer, Gerd ^a   Hörl, Walter H ^a   Böhmig, Georg A ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Alloantibodies; C4d; Immunosuppression; Kidney transplantation; Rejection

Indexed keywords

CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C4D; CYCLOSPORIN; CYCLOSPORIN A; FINGOLIMOD; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; ARTICLE; COHORT ANALYSIS; COMPLEMENT DEPOSITION; DIAGNOSTIC VALUE; DISEASE MARKER; EVALUATION; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; STAINING;

ADULT; BIOPSY; CADAVER; CAPILLARIES; COHORT STUDIES; COMPLEMENT C4; COMPLEMENT C4B; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MIDDLE AGED; ODDS RATIO; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 19244365301     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000128344.94808.03     Document Type: Article

References (25)

1. Böhmig G, Regele H. Diagnosis and treatment of antibody-mediated kidney allograft rejection. Transpl Int 2003; 16: 773.
2. Feucht HE. Complement C4d in graft capillaries: The missing link in the recognition of humoral alloreactivity. Am J Transplant 2003; 3: 646.
3. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria: An addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708.
4. Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333.
5. Regele H, Exner M, Watschinger B, et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001; 16: 2058.
6. Lederer SR, Kluth-Pepper B, Schneeberger H, et al. Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts. Kidney Int 2001; 59: 334.
7. Mauiyyedi S, Crespo M, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779.
8. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: A specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13: 1091.
9. Nickeleit V, Zeiler M, Gudat F, et al. Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242.
10. Herzenberg AM, Gill JS, Djurdiev O, et al. C4d deposition in acute rejection: An independent long-term prognostic factor. J Am Soc Nephrol 2002; 13: 234.
11. Pascual M, Saidman S, Tolkoff-Rubin N, et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998; 66: 1460.
12. Theruvath TP, Saidman SL, Mauiyyedi S, et al. Control of antidonor antibody production with tacrolimus and mycophenolate mofetil in renal allograft recipients with chronic rejection. Transplantation 2001; 72: 77.
13. Luo H, Chen H, Daloze P, et al. Inhibition of in vitro immunoglobulin production by rapamycin. Transplantation 1992; 53: 1071.
14. Propper DJ, Woo J, Macleod AM, et al. The effects of rapamycin on humoral immunity in vivo: Suppression of primary responses but not of ongoing alloantibody synthesis or memory responses. Transplantation 1992; 54: 1058.
15. Canadian Neoral Renal Transplantation Study Group. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation 2001; 72: 1024.
16. Clase CM, Mahalati K, Kiberd BA, et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling. Am J Transplant 2002; 2: 789.
17. Smits JMA, Persijn GG, van Houwelingen HC, et al. Evaluation of the Eurotransplant senior program: The results of the first year. Am J Transplant 2002; 2: 664.
18. Haas M, Böhmig GA, Leko-Mohr Z, et al. Peri-operative immunoadsorption in sensitized renal transplant recipients. Nephrol Dial Transplant 2002; 17: 1503.
19. Böhmig GA, Regele H, Exner M, et al. C4d-positive acute humoral renal allograft rejection: Effective treatment by immunoadsorption. J Am Soc Nephrol 2001; 12: 2482.
20. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
21. Hosmer DW, Lemeshow S. Applied logistic regression. New York, NY: John Wiley & Sons 1989, pp 135-175.
22. Krönke M, Leonard WJ, Depper JM, et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984; 81: 5214.
23. Knechtle SJ, Pirsch JD, H Fechner J Jr, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722.
24. Haas M, Ratner LE, Montgomery RA. C4d staining of perioperative renal transplant biopsies. Transplantation 2002; 74: 711.
25. Fiebeler A, Mengel M, Merkel S, et al. Diffuse C4d deposition and morphology of acute humoral rejection in a stable renal allograft. Transplantation 2003; 76: 1132.